Carisma Therapeutics (CARM) Stock Price, News & Analysis

Company Overview

Carisma Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors. In parallel, Carisma is advancing CT-381, an engineered myeloid cell therapy designed to modulate inflammatory and autoimmune conditions. Preclinical data have demonstrated robust antigen-dependent activation, tumor penetration and anti-tumor efficacy in multiple models, supporting the progression of these programs toward their first clinical studies.

Carisma’s interdisciplinary team combines expertise in myeloid biology, genetic engineering and translational medicine. The company partners with leading academic institutions and specialized contract development and manufacturing organizations to establish scalable, GMP-compliant processes for its cell therapies. By uniting macrophage biology with CAR engineering, Carisma Therapeutics seeks to create a novel class of treatments with broad applications across oncology and immune-mediated diseases.

Key Stats

• Today's Range: $0.34 to $0.39
• 50-Day Range: $0.22 to $0.45
• 52-Week Range: $0.14 to $1.27
• Volume: 859,286 shs
• Average Volume: 8.19 million shs
• Market Capitalization: $14.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.93
• Consensus Rating: Moderate Buy

Carisma Therapeutics Stock Analysis - MarketRank™

Carisma Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 574th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Carisma Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Upside Potential

Carisma Therapeutics has a consensus price target of $1.93, representing about 440.7% upside from its current price of $0.36.

Amount of Analyst Coverage

Carisma Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.32) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Carisma Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Carisma Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.21% of the float of Carisma Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Carisma Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carisma Therapeutics has recently increased by 40.40%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Carisma Therapeutics does not currently pay a dividend.

Dividend Growth

Carisma Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.21% of the float of Carisma Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Carisma Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carisma Therapeutics has recently increased by 40.40%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.45

News Sentiment

Carisma Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Carisma Therapeutics this week, compared to 1 article on an average week.

Search Interest

9 people have searched for CARM on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.

MarketBeat Follows

7 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Carisma Therapeutics is held by insiders.

Percentage Held by Institutions

44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CARM Stock Analysis - Frequently Asked Questions

How have CARM shares performed this year?

Carisma Therapeutics' stock was trading at $0.4188 at the beginning of 2025. Since then, CARM shares have decreased by 15.0% and is now trading at $0.3560.

How were Carisma Therapeutics' earnings last quarter?

Carisma Therapeutics Inc. (NASDAQ:CARM) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.05. The firm earned $3.65 million during the quarter, compared to the consensus estimate of $2.47 million.

Who are Carisma Therapeutics' major shareholders?

Carisma Therapeutics' top institutional investors include Jane Street Group LLC (0.36%).

How do I buy shares of Carisma Therapeutics?

Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Carisma Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CARM
• CIK: 1485003
• Web: N/A
• Phone: 617-444-8550
• Fax: 617-858-0911
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Carisma Therapeutics: $1.93
• High Price Target: $5.00
• Low Price Target: $0.70
• Potential Upside/Downside: +414.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.48 million
• Net Margins: -254.28%
• Pretax Margin: -458.60%
• Return on Equity: N/A
• Return on Assets: -192.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.48
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: $19.63 million
• Price / Sales: 0.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.67) per share
• Price / Book: -0.56

Miscellaneous

• Outstanding Shares: 41,790,000
• Free Float: 38,905,000
• Market Cap: $15.63 million
• Optionable: No Data
• Beta: 1.82